Acadian Asset Management
AKBA icon

Acadian Asset Management’s Akebia Therapeutics AKBA Stock Holding History

Acadian Asset Management’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.56M Buy
4,004,867
+2,627,799
+191% +$3.13M 0.01% 828
2026
Q1 		$1.91M Sell
1,377,068
-822,679
-37% -$1.13M ﹤0.01% 975
2025
Q4 		$3.54M Buy
2,199,747
+51,796
+2% +$108K 0.01% 741
2025
Q3 		$5.86M Buy
2,147,951
+797,766
+59% +$2.65M 0.01% 609
2025
Q2 		$4.91M Buy
+1,350,185
New +$3.71M 0.01% 589
2024
Q3 		– Sell
-4,063,383
Closed -$4.14M – 2062
2024
Q2 		$4.14M Sell
4,063,383
-1,246,372
-23% -$1.54M 0.01% 547
2024
Q1 		$9.71M Sell
5,309,755
-1,605,748
-23% -$2.57M 0.03% 309
2023
Q4 		$8.57M Sell
6,915,503
-307,985
-4% -$314K 0.03% 326
2023
Q3 		$8.23M Sell
7,223,488
-236,865
-3% -$304K 0.03% 323
2023
Q2 		$6.82M Sell
7,460,353
-22,700
-0.3% -$21.9K 0.03% 375
2023
Q1 		$4.19M Hold
7,483,053
– – 0.02% 505
2022
Q4 		$4.32M Hold
7,483,053
– – 0.02% 483
2022
Q3 		$2.37M Buy
7,483,053
+144,010
+2% +$56.5K 0.01% 586
2022
Q2 		$2.59M Buy
+7,339,043
New +$3.08M 0.01% 568
2021
Q3 		– Sell
-10,636
Closed -$40K – 1698
2021
Q2 		$40K Buy
10,636
+8,536
+406% +$28.7K ﹤0.01% 1831
2021
Q1 		$7K Sell
2,100
-833,985
-100% -$3M ﹤0.01% 2016
2020
Q4 		$2.34M Buy
836,085
+116,768
+16% +$341K 0.01% 717
2020
Q3 		$1.8M Buy
719,317
+715,611
+19,310% +$6.28M 0.01% 698
2020
Q2 		$50K Buy
+3,706
New +$38.3K ﹤0.01% 1917
2018
Q4 		– Sell
-73,516
Closed -$649K – 1710
2018
Q3 		$649K Sell
73,516
-27,158
-27% -$243K ﹤0.01% 829
2018
Q2 		$1M Sell
100,674
-199,758
-66% -$2M ﹤0.01% 727
2018
Q1 		$2.86M Sell
300,432
-324,735
-52% -$4.54M 0.01% 519
2017
Q4 		$9.3M Sell
625,167
-103,062
-14% -$1.71M 0.04% 289
2017
Q3 		$14.3M Buy
728,229
+357,491
+96% +$5.5M 0.06% 237
2017
Q2 		$5.33M Buy
370,738
+74,179
+25% +$940K 0.02% 383
2017
Q1 		$2.73M Buy
+296,559
New +$2.9M 0.01% 543

Other funds holding AKBA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Acadian Asset Management's AKBA Position: Q2 2026 in Review

Acadian Asset Management increased its Akebia Therapeutics (AKBA) stake by 191% in Q2 2026, buying an estimated $3.13M and bringing the position to 4,004,867 shares worth $4.56M. The position accounts for 0.01% of the portfolio, ranked #828.

Acadian Asset Management first reported a position in AKBA in Q1 2017 and has held it in 26 quarters since. The position peaked at $14.3M in Q3 2017. 171 funds tracked by Wall St. Rank hold AKBA as of Q2 2026.

  • Acadian Asset Management held 4,004,867 shares of Akebia Therapeutics worth $4.56M as of Q2 2026.
  • Acadian Asset Management bought 2,627,799 Akebia Therapeutics shares in Q2 2026, an estimated $3.13M.
  • Akebia Therapeutics made up 0.01% of Acadian Asset Management's portfolio in Q2 2026, its #828 holding.
  • Acadian Asset Management first reported a position in Akebia Therapeutics in Q1 2017 and has held it in 26 quarters since.
  • Acadian Asset Management's Akebia Therapeutics position peaked at $14.3M in Q3 2017.
  • 171 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q2 2026.

Based on Acadian Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.